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Several groups have examined the possible use of radioiodinated cholesterol esters to 
achieve selective uptake of radioactivity in the adrenal cortex and have obtained 
variable results. This study indicates that the tissue distribution profile varies not only 
with the type of ester, but also with the vehicle employed for administration. 
Radioiodinated 19-iodocholesterol (125IQ iodocholesteryl palmitate (12HCP) and 
iodocholesteryl oleate (125-ICO) were dissolved in either tween vehicle (saline con- 
taining 1.6% tween 80 and 10% ethanol) or myristate vehicle (isopropyl myristate 
ethanol, 1: 5 v/v) and administered i.v. to rats. Irrespective of the agent, considerably 
more radioactivity appeared in the target organs when the tween vehicle was 
employed. When the myristate vehicle was used, higher levels of radioactivity 
appeared in the lung. This finding suggests precipitation of the agents from the 
myristate vehicle occurred upon administration. In the tween vehicle, 125ICO 
showed almost three times greater predilection for adrenal cortex than 125ICP with 
levels of activity approaching those seen for 125-K. Adrenal activity and adrenal to 
non-target ratios were sufficient for visualization of the adrenals at 5 days after 
injection of 125-ICO in the tween vehicle. Lipid extraction and TLC analysis of tissue 
radioactivity revealed that radioactivity in the adrenal and ovary was predominantly 
in an esterified form. Further analysis of the esters present after injection of 125-ICP 
showed these to be a mixture of mono and polyunsaturated esters. The site of hy- 
drolysis and subsequent reesterification is an interesting biochemical aspect that 
remains to be elucidated. 
Introduction 
RADIOIODINATED derivatives of cholesterol have been used successfully to image the 
adrenal gland and related tumors. Since cholesterol is present in the circulation predomi- 
nantly in an esterified form, several groups have examined the possible use of radioiodin- 
ated cholesterol esters to achieve selective uptake of radioactivity in the adrenal cortex 
with variable results. A previous report from this laboratory’” suggested that in contrast 
to 19-radioiodinated cholesterol which showed selective concentration in the adrenal 
cortex following various routes of administration, esters of 19-radioiodinated cholesterol 
(acetate and palmitate) produced high concentrations of radioactivity in the adrenal only 
after oral administration. A preliminary experiment with 19-radioiodinated cholesteryl 
oleate, however, resulted in selective accumulation of activity in the adrenal gland. This 
result, as well as a recent report (2) showing selective adrenal uptake after administration 
of radioiodinated cholesterol esters prompted a re-examination of 19-radioiodinated 
cholesterol esters as organ or tumor-imaging agents for the adrenal cortex. 
Materials and Methods 
Radioiodinated 194odocholesterol (125-IQ 194odocholesteryl palmitate (125-ICP) 
and 194odocholesteryl oleate (125ICO) were prepared as previously described.“*3’ The 
* To whom reprint requests should be sent. 
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compounds were formulated for injection by dissolving in either tween vehicle (1.60; 
tween 80 and 10% ethanol in saline) or myristate vehicle (isopropyl myristate-ethanol, 
1: 5 v/v). Prior to use, radiochemical purity of each compound was determined by thin- 
layer chromatography (TLC) using silicagel plates (Eastman Kodak) developed in benzene- 
ethyl acetate, 9: 1 v/v (system 1) and/or carbon tetrachloride (system 2). In addition, 
aliquots of each solution were assayed in a well-scintillation counter* to determine the 
radioactive concentration of each solution. 
Tissue distribution studies 
Thirty female Sprague-Dawley rats? weighing 200-250 g were used as experimental 
animals. The rats were housed in temperature and light-controlled quarters and had free 
access to food$ and water. Prior to injection, the rats were monitored for stage of estrous 
cycle by vaginal smear. The rats were divided into six groups and each group received an 
i.v. injection of one of the following: 125IC (25.8 $i 0.057 mg-‘) in 0.25 ml tween: 
125-IC (24.3 &i 0.12 mg- ‘) in 0.10 ml myristate; 125-ICP (16.5 &i 0.22 mg-‘) in 0.30 ml 
tween; 125-ICP (20.4 ,&i 0.18 mg-‘) in 0.15 ml myristate; 125-ICO (30.8 &i 0.22 mg-‘) 
in 0.25 ml tween; or 125-ICO (24.0 PCi 0.24 mg- ‘) in 0.10 ml myristate. The rats were 
killed by exsanguination from the heart while under ether anesthesia at 24 h post injec- 
tion. Samples of adrenal cortex, blood, liver, lung, ovary, spleen and thyroid were placed 
in tared cellulose acetate capsules and weighed. The samples were assayed for radioac- 
tivity in a well-scintillation counter for 10 min or until 40,000 counts had accummulated. 
Counting efficiency for lz51 was 84%. In addition, samples of tissues were frozen for 
subsequent extraction studies. 
Adrenal scan 
A female Sprague-Dawley rat (211 g) was given an i.v. injection of 125-ICO (123 &i 
0.88 mg-‘) in 1.0 ml tween. At 1 and 5 days following administration, the rat was anes- 
thetized by i.p. injection of 0.2 ml sodium pentobarbital (50mgml-‘). The rat was 
scanned in the prone position using a Berthold Radiochromatogram Scanner (LB2723) 
with small animal scanning attachments. After the 5 day scan, the rat was killed and 
selected tissues assayed for radioactivity as previously described. 
Extraction studies 
Extraction of tissue lipids was performed as previously describedr4) except that TLC 
analysis of the lower phase was performed on silica gel plates developed in solvent 
system 1 for all samples. In addition, samples from rats that received 125-ICP were also 
analyzed using solvent system 2. Cholesterol and its palmitate, oleate, linoleate and 
,arachidonate esters and 1Piodocholesterol and its palmitate, oleate and linoleate esters 
were chromatographed simultaneously and used as reference standards. 
Results and Discussion 
The results of tissue distribution studies with 125-IC and its palmitate and oleate esters 
administered in either tween or myristate have been summarized in Table 1. Irrespective 
of the agent administered, concentration of radioactivity in the adrenal cortex was 
greater when the tween vehicle was used as compared to the myristate vehicle. This 
difference was most noticeable when the oleate was administered (17 times greater) as 
compared to the palmitate (5 times greater) or the free sterol (2 times greater). A similar 
pattern was noted for activity m the ovary. Thyroid activity, generally considered to be 
an indicator of in uivo deiodination, was also much higher when the compounds were 
administered in the tween vehicle. Thus, the injection vehicle appeared to be an import- 
ant factor in the distribution profiles of 125-IC esters and, to a lesser extent, 125-IC. 
- 
* Searle 1185 Automatic Gamma System. 
t Spartan Research Animals Inc., Hasslett, MI. 
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Irrespective of the vehicle, higher levels of radioactivity accumulated in the adrenal 
following administration of 125-K rather than the esterified forms. 
In addition to vehicle, the ester portion of the molecule appeared to influence the 
tissue distribution profile of these agents. When the more appropriate tween vehicle was 
used for injection, tissue levels of radioactivity were consistently higher when 125-ICO 
was injected as compared to 125ICP, and activity in the target tissues (adrenal cortex 
and ovary) was closer to that seen when the free sterol was administered. Although 
greater target radioactivity following administration of 125ICO may be related to the 
oleate specificity reported for many metabolic processes (e.g. chylomicron specificity for 
oleate formation, liver soluble cholesterol esterase preference for oleate, liver specificity 
for oleate formation with oleate present as the major liver ester), other esters must be 
studied to confirm that oleate is the preferred ester. FUKUSHI et al.,“’ however, have noted 
‘that adrenal levels of radioactivity following administration of radioiodinated cholesteryl 
acetate were also similar to radioiodinated cholesterol. 
The results of extraction of lipid-soluble tissue radioactivity followed by TLC analysis 
of the extract have been summarized in Tables 2 and 3. Most of the radioactivity present 
in all tissues analyzed was extractable into the organic phase. Radioactivity which comi- 
grated with both the free and esterified standards in system 1 was present in all tissue 
extracts. In the target tissues, adrenal and ovary, the greater percentage of activity was 
found to comigrate with the esterified standards. These results are in agreement with 
those previously reported for 125-IC. (4) When the tissue extracts from rats that received 
125-I@ were analyzed by TLC to separate esters by degree of saturation, most of the 
TABLE 2. Results of TLC analysis of lipid-soluble radioactivity from tissue of rats that received 
19-radioiodinated cholesterol esters 
- 
TLC analysis of organic phase 
Compound ‘:/, of Tissue radioactivity benzene-ethyl acetate (9 : 1 v/v)* 
and extracted into organic 
tissue phase* vji Free o/;, Esterified 
125~ICP Tweent 
Adrenal cortex 81.4 * 0.8 14.7 k 2.6 70.0 * 5.8 
Plasma 70.4 &- 3.1 29.6 + 3.0 63.1 + 6.5 
Liver 61.3 + 0.8 46.6 k 2.7 29.0 + 1.9 
Ovary 72.6 + 0.8 17.0 f 2.1 69.0 + 2.0 
125-ICP Myristatet 
Adrenal cortex . 77.2 k 1.9 26.4 f 2.8 53.8 + 7.2 
Plasma 56.5 + 5.0 22.5 k 0.7 36.2 &- 0.5 
Liver 81.2 + 1.5 55.1 * 2.2 32.7 5 3.1 
Ovary 83.5 f 1.1 23.5 f 1.8 45.2 + 1.4 
125X0 Tween 
Adrenal cortex 90.9 f 1.8 13.8 f 1.0 68.5 rt 5.2 
Blood 69.4 k 3.7 51.5 * 1.5 34.6 k 1.6 
Liver 78.5 + 1.8 55.4 If: 4.9 27.4 5 6.6 






86.8 * 1.3 22.2 & 4.3 62.9 + 0.8 
56.9 + 3.6 71.9 f 1.1 21.6 + 0.8 
82.3 ) 0.7 35.3 + 2.0 46.8 k 4.9 
83.2 + 3.0 32.2 + 8.3 46.7 + 3.7 
* Values represent mean + SEM. n = 3, 4 or 5. 
t Tween vehicle (1.6% tween 80 and 10% ethanol in saline). 
$: Myristate vehicle (Isopropyl myristate-ethanol, 1: 5, v/v). 
125-ICP = 125-I-19-iodocholesteryl palmitate. 
125-IC = 125-I-19-iodocholesteryl oleate. 
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TABLE 3. Results of TLC analysis of lipid-soluble radioactivity from tissues of rats that received 
125ICP; separation of esters by degree of fatty acid saturation 
% of Total radioactivity on plate present in each band* 
Tissue Origin Arach Linol Oleate Palm 
Adrenal cortex 17.0 13.4 2.5 2.8 3.9 
Plasma 30.0 9.1 10.7 2.4 1.4 
Liver 67.5 3.4 2.3 2.0 2.5 
Ovary 44.4 13.4 7.9 4.2 15.1 
125ICP control 2.9 2.0 2.2 22.2 64.3 
125~ICP = 125-I-19Godocholesteryl palmitate administered in the tween vehicle (1.6% tween 80 
and 10% ethanol in saline). 
* Bands named according to migration of TLC standards. 
Origin-Free cholesterol, highly unsaturated esters and other polar metabolites. 
Arach-Cholesteryl arachidonate. 
Linol-Cholesteryl and 19-iodocholesteryl linoleate. 
Oleate-Cholesteryl and 19-iodocholesteryl oleate. 
Palm--Cholesteryl and 19-iodocholesteryl palmitate. 
radioactivity comigrated with standards containing unsaturated fatty acids. This suggests 
that when the 125~ICP was injected, there was hydrolysis of the ester and reesterification 
with a different fatty acid. This has also been reported to be the case when ~E-~H- 
cholesterol 1-l 4C-palmitate was injected in man. t6) The sites for this hydrolysis and 
reesterification have yet to be defined. 
Based on these and other studies concerning the disposition of administered choles- 
terol and cholesterol ester, the vehicle used for administration can influence the results in 
at least two ways. First, the detergent action of the tween vehicle facilitates not only the 
solubility of cholesterol derivatives in plasma, but also their incorporation into lipopro- 
teins for subsequent transport to target tissues. The absence of such a solubilizing com- 
ponent in the myristate vehicle may result in precipitation of these lipophilic agents from 
solution when injected into the blood. Precipitated material would be expected to 
become entrapped in the capillaries of the lung. Although samples of lung were taken 
only when 125-ICP was injected, radioactivity in the lung was greater when myristate 
was used as the vehicle for administration. 
Secondly, it is currently unknown whether it is essential for cholesterol esters to be 
hydrolyzed to free cholesterol prior to uptake by steroid synthesizing tissues such as 
adrenal and ovary. DEXTER et al. (‘) have shown that nonesterified plasma cholesterol is 
more efficiently incorporated into adrenal tissue than plasma cholesterol palmitate, and 
this is consistent with our findings with 125-K and 125-ICP. If hydrolysis of the esters to 
free 125-IC is an important factor in tissue uptake, the physical state of the administered 
esters could be critical. For example, VAHOUNY et al. @) have previously shown that 
cholesterol oleate in micellar form is rapidly hydrolyzed by pancreatic juice cholesterol 
esterase, whereas albumin-stabilized cholesterol oleate is a very poor substrate for this 
enzyme. Administration of 125-ICO in myristate could have a similar retarding effect on 
the subsequent hydrolysis to free 125-IC. 
Based on the results of the tissue distribution studies, 125-ICO in the tween vehicle 
was used in an attempt to image the rat adrenal gland. At the 1 day interval, an area of 
activity thought to represent the right adrenal was evident. The left adrenal, however, 
was not resolved because of a large area of activity associated with the spleen. At 5 days, 
however, the adrenals and the thyroid were clearly evident. The levels of radioactivity 
(“/o Administered Dose g tissue- ‘) for selected tissues of this rat at 5 day post injection were: 
adrenal cortex-7.858, blood-O.01 8, kidney-0.025, liver-O. 141, ovary-1.286, 
spleen-Q.03 1 and thyroid-l 93.104. 
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Conclusions 
1. The tissue distribution profiles of 125-K, 125-ICO and 125-ICP were affected by the 
injection vehicle used. The myristate vehicle is unsuitable for achieving target tissue 
selectivity of 125-K and its esters. 
2. Both 125-ICO and 125-ICP showed selective concentration of radioactivity in the 
adrenal cortex when administered in the tween vehicle with 125-ICO showing greater 
predilection than 125-ICP. 
3. Injection of 125-ICO in the tween vehicle resulted in a concentration of radioactivity 
in the adrenal cortex sufficient to afford a positive image at 5 days post injection when 
the rat was scanned with a small animal scanner. 
4. 125-ICP was hydrolyzed and reesterified with unsaturated fatty acids in vim. 
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